Neurogene Quote - NGNE | ADVFN
ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Neurogene Inc

Neurogene Inc (NGNE)

21.49
0.00
(0.00%)
Closed 10 January 8:00AM
0.00
0.00
(0.00%)
Advanced chart

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
21.49
Bid
20.52
Offer
23.48
Volume
-
0.00 Day's Range 0.00
14.44 52 Week Range 74.49
Market Cap
Previous Close
21.49
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
424,476
Shares Outstanding
14,854,725
Dividend Yield
-
PE Ratio
-8.79
Earnings Per Share (EPS)
-2.44
Revenue
-
Net Profit
-36.32M

About Neurogene Inc

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional ge... Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Neurogene Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NGNE. The last closing price for Neurogene was US$21.49. Over the last year, Neurogene shares have traded in a share price range of US$ 14.44 to US$ 74.49.

Neurogene currently has 14,854,725 shares in issue. The market capitalisation of Neurogene is US$319.23 million. Neurogene has a price to earnings ratio (PE ratio) of -8.79.

NGNE Latest News

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndrome Neurogene to advance NGN-401 at 1E15 vg dose Expects to provide an update on...

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update...

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed...

Neurogene Announces Oversubscribed $200 Million Private Placement

Financing included participation from top-tier healthcare funds Proceeds expected to fund Company into the second half of 2027 Company to host webcast to review interim clinical data from Phase...

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (Nasdaq: NGNE), a...

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

NGN-401 gene therapy for Rett syndrome received RMAT designation from FDA based on preliminary clinical evidence indicating the potential to address unmet medical needs NGN-401 selected for FDA...

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in Rett syndrome RMAT designation provides an...

Neurogene to Participate in BMO Genetic Medicines Summit

Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that...

Neurogene Announces Addition to Russell 3000® Index

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that...

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile Interim safety data presented at the International Rett Syndrome Foundation (IRSF...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2-8.5142613878223.492420.6521162822.58284755CS
4-1.43-6.2390924956422.9225.3520.6525006422.85899911CS
12-31.98-59.809238825553.4774.4914.4442447630.06103879CS
26-15.06-41.203830369436.5574.4914.4425323232.8419074CS
52-3.62-14.416567104725.1174.4914.4418574634.11239624CS
1566.9247.494852436514.5774.4912.4918063433.78373594CS
2606.9247.494852436514.5774.4912.4918063433.78373594CS

NGNE - Frequently Asked Questions (FAQ)

What is the current Neurogene share price?
The current share price of Neurogene is US$ 21.49
How many Neurogene shares are in issue?
Neurogene has 14,854,725 shares in issue
What is the market cap of Neurogene?
The market capitalisation of Neurogene is USD 319.23M
What is the 1 year trading range for Neurogene share price?
Neurogene has traded in the range of US$ 14.44 to US$ 74.49 during the past year
What is the PE ratio of Neurogene?
The price to earnings ratio of Neurogene is -8.79
What is the reporting currency for Neurogene?
Neurogene reports financial results in USD
What is the latest annual profit for Neurogene?
The latest annual profit of Neurogene is USD -36.32M
What is the registered address of Neurogene?
The registered address for Neurogene is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19802
What is the Neurogene website address?
The website address for Neurogene is www.neoleukin.com
Which industry sector does Neurogene operate in?
Neurogene operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 17.60
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 71.1445
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.60
(0.00%)
0
AACGATA Creativity Global
US$ 0.9791
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 17.60
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 71.1445
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.60
(0.00%)
0
AACGATA Creativity Global
US$ 0.9791
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 17.60
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 71.1445
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.60
(0.00%)
0
AACGATA Creativity Global
US$ 0.9791
(0.00%)
0

NGNE Financials

Financials

Your Recent History

Delayed Upgrade Clock